Niagen (nicotinamide riboside) / ChromaDex - LARVOL DELTA

Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis. (PubMed, Int J Surg) - "SIRT3 regulates ferroptosis by inhibiting excessive mitophagy in osteoblasts, providing a novel mechanistic pathway for mitigating GIOP. These findings suggest that SIRT3 represents a critical regulator of mitophagy-dependent ferroptosis and a potential therapeutic target for GIOP."

Journal • Osteoporosis • Rheumatology • SIRT3

NAD+ repletion enhances mammary lactogenesis and improves offspring development in a sow model. (PubMed, J Nutr) - "NR supplementation meets lactating mammary NAD+ demands, restoring NAD+ levels to potentiate secretory differentiation and milk biosynthesis, identifying novel biomarkers and therapeutic targets for lactation insufficiency."

Journal • Anesthesia • Gastrointestinal Disorder

Immature Acta2R179C/+ smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS. (PubMed, Nat Commun) - "Increasing mitochondrial respiration with nicotinamide riboside (NR) drives differentiation and decreases migration of Acta2R179C/+ SMCs. Carotid artery injury of Acta2SMC-R179C/+ mice leads to premature death, intraluminal SMC accumulation leading to MMD-like occlusive lesions, neurologic symptoms, and neuron loss, whereas injured WT mice have none of these phenotypes, and all are prevented by NR treatment in the Acta2SMC-R179C/+ mice. These data show that driving differentiation and quiescence of Acta2R179C/+ SMCs by altering cellular metabolism attenuates MMD-like disease in the Acta2SMC-R179C/+ mice, highlighting a role of immature and highly migratory SMCs in the pathogenesis of MMD."

Journal • Preclinical • Vascular Neurology • ACTA2

Nicotinamide Riboside Supplementation Alleviates Heat Stress-Induced Testicular Damage and Improves Semen Quality in Boars. (PubMed, Mol Nutr Food Res) - "NR supplementation also improved semen quality, reduced spermatogenesis defects, and attenuated oxidative stress and inflammation induced by HS. These findings highlight the potential of NAD+ precursors as a promising nutritional strategy to mitigate the adverse effects of HS on male reproductive health."

Journal • Inflammation

Clinical and instrumental diagnostics of facial neuropathy in children (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "A review of the literature and the authors' own long-term experience of developing and implementing into practice an algorithm for clinical and instrumental diagnostics of facial nerve neuropathy in children are presented, allowing, in the early stages of the disease, taking into account the identified values of prognostically significant indicators, to predict the outcome of the disease and develop an individual medical rehabilitation program to achieve maximum restoration of nerve function. The expediency of using Cytoflavin (Inosine+Nicotinamide+Riboflavin+Succinic acid) as a drug with complex action in the treatment of severe neuropathies of the facial nerve is reflected."

Journal • Review • Pain

Vitamin B3 Ameliorates Sleep Duration and Quality in Clinical and Pre-Clinical Studies. (PubMed, Nutrients) - "Supplementation with nicotinamide riboside (NR), also known as a form of vitamin B3, a biochemical precursor of NAD+, may replenish this depletion...More research is warranted to understand the impacts of NR on sleep for women. NR supplementation is a reliable and effective alternative to boost NAD+ levels and may ameliorate sleep patterns."

Journal • Preclinical • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Fatigue • Insomnia • Sleep Disorder • ARNTL • BMAL1 • PER2

Mitochondrial Unfolded Protein Response (mtUPR) Activation Improves Pathological Alterations in Cellular Models of Ethylmalonic Encephalopathy. (PubMed, Antioxidants (Basel)) - "We also identified a cocktail of compounds consisting of pterostilbene, nicotinamide, riboflavin, thiamine, biotin, lipoic acid, and L-carnitine that improved the cellular and metabolic alterations...In conclusion, personalised precision medicine in EE using patient-derived cellular models can be an interesting approach for the screening and evaluation of potential therapies. In addition, the activation of the SIRT3 axe of mtUPR is a promising therapeutic strategy for rescuing ETHE1 pathogenic variants."

Journal • CNS Disorders • Gastrointestinal Disorder • Metabolic Disorders • SIRT3

PT-SILAOX: Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress (clinicaltrials.gov) - P=N/A | N=14 | Not yet recruiting | Sponsor: Fundació Eurecat

New trial

Defective Mitochondrial Respiration in Hereditary Thoracic Aneurysms. (PubMed, Cells) - "Notably, nicotinamide riboside, a NAD+ precursor, restores mitochondrial respiration, increases Tfam and mtDNA levels, and promotes a contractile phenotype by enhancing actin polymerization and reducing matrix metalloproteinase activity. These findings identify mitochondrial dysfunction as a shared feature in hereditary thoracic aortic aneurysm, not only in Marfan syndrome, but also in other genetic forms, and highlight mitochondrial boosters as a potential therapeutic strategy."

Journal • Cardiovascular • Genetic Disorders • Metabolic Disorders • ACTA2 • TFAM

Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment. (PubMed, Nat Immunol) - "Supplementation with nicotinamide riboside (a nicotinamide adenine dinucleotide precursor) and honokiol (a SIRT3 activator) enhanced NK cell cytotoxicity by reducing cellular Kla levels. This combination restores antileukemic activity of NK cells in vivo and ex vivo by modulating Kla on ROCK1, thereby inhibiting ROCK1-DRP1 signaling to prevent mitochondrial fragmentation. Altogether, this study shows how lactylation can compromise NK cells and highlights this lactylation as a target for NK cell-based immunotherapy to enhance resilience to lactate in the tumor microenvironment."

Biomarker • Journal • Oncology • SIRT3

Network of nicotinamide mononucleotide biosynthesis: substrate tracking, rate-limiting enzyme, and regulatory strategy. (PubMed, Synth Syst Biotechnol) - "First, we systematically trace four substrates (nicotinamide ribose, nicotinamide, niacin, and nicotinamide adenine dinucleotide) and their respective metabolic routes...Through comparative analysis, the most promising biosynthetic pathway and prospects are discussed. Additionally, this review also provides original perspectives for NMN industrial development."

Journal • Review

Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial. (PubMed, J Pharmacol Exp Ther) - P1/2 | "This pilot study provides critical evidence by examining peripheral endothelial function, cerebrovascular responses, and cognitive performance. Its multifaceted approach lays the groundwork for future trials to refine effect sizes and validate NR's potential to counter vascular aging and cognitive decline in PAD."

Journal • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Peripheral Arterial Disease

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial. (PubMed, Aging Cell) - "NR treatment significantly improved arterial stiffness, as indicated by CAVI, and likely suppressed renal functional decline in patients with WS. Therefore, NR may be beneficial for preventing atherosclerosis, skin ulcers, and kidney dysfunction in patients with WS."

Journal • Atherosclerosis • Cardiovascular • Metabolic Disorders • Nephrology • Renal Disease • Sarcopenia • WRN

NOPARK Open Label Extension Study (clinicaltrials.gov) - P=N/A | N=400 | Active, not recruiting | Sponsor: Haukeland University Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date

Long-Term Functional and Structural Renoprotection After Experimental Acute Kidney Injury in Subclinical Chronic Kidney Disease In Vivo. (PubMed, Int J Mol Sci) - "Dual treatment boosting nicotinamide adenine dinucleotide (NAD) by nicotinamide riboside (NR) combined with the mitochondria-targeted antioxidant SkQR1 protected the KFR and reduced structural kidney damage, including markers of vascular integrity and the relative blood volume (rBV). The dual treatment upregulated Sirt1 and Nrf2, increased the nuclear localisation of the mitochondrial biogenesis regulator PGC-1α and the mitochondrial protein marker COX4, and upregulated the antioxidant gene NOQ1. These observations suggest mitochondrial protection and modulation of the cellular redox state provided long-term structural and functional protection against kidney injury superimposed on background sCKD."

Journal • Preclinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease • Reperfusion Injury

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients (clinicaltrials.gov) - P2 | N=115 | Recruiting | Sponsor: Christopher Kai Shun Leung

New P2 trial • Glaucoma • Ophthalmology

Effect of Nicotinamide Riboside Supplementation on aPL Induced Placental Trophoblast Dysfunction (ASRI 2025) - "Nicotinamide riboside supplementation reversed the ability of aPL to induce human trophoblast inflammation and reversed some of the trophoblast angiogenic dysfunction in response to aPL. However, NR was unable to reverse the aPL-induced trophoblast migratory dysfunction. In summary, NR supplementation mitigated some but not all aPL induced placental trophoblast dysfunction."

Genetic Disorders • Gynecology • Hematological Disorders • Inflammation • Obstetrics • CXCL8 • IL1B • IL6

MPMA: Matching Perfusion and Metabolic Activity in HFpEF (clinicaltrials.gov) - P2 | N=53 | Recruiting | Sponsor: University of Pennsylvania | Trial completion date: Jan 2026 ➔ May 2027 | Trial primary completion date: Jan 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer (clinicaltrials.gov) - P=N/A | N=20 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Nicotinamide riboside alleviates heat stress-induced intestinal barrier dysfunction in mice. (PubMed, Shock) - "The protective effect of NR on mouse intestinal barrier against heat is associated with reduced inflammation and oxidative stress. However, NR has no effect on heat-induced intestinal mitochondrial dysfunction."

Journal • Preclinical • Cardiovascular • CNS Disorders • Inflammation • Metabolic Disorders • IL6 • TNFA

NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: Haukeland University Hospital

New P2 trial

Differential mitochondrial function drives sex differences in T cell exhaustion (IMMUNOLOGY 2025) - "Treatment with antioxidant (N-acetylcysteine) or mitophagy inducer (nicotinamide riboside) mitigated the sex differences in exhausted phenotype in T cells, suggesting that differences in mitochondria function may be a driver of sex differences in T cell exhaustion. Furthermore, combining anti-PD1 and 4-1BB agonist antibodies, which enhance mitochondrial function in T cells, improved survival of both male and female pre-clinical GBM models. These findings suggest that differential mitochondrial dysfunction drives sex differences in T cell exhaustion, offering a target for sex-specific therapies.Keywords: Cells T Cells; Processes Cell Activation Costimulation Cytotoxicity Inflammation"

IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Metabolic Disorders • Oncology • Solid Tumor

NAD replenishment restores mitochondrial function and thermogenesis in the brown adipose tissue of mice with obesity. (PubMed, J Physiol) - "NAD+ metabolism enzymes Nampt and NMNat3 are crucial for mitochondrial function in BAT. Nicotinamide riboside treatment increases the expression of key thermogenic proteins and NAD+-related enzymes in BAT, optimizing adaptive thermogenesis and mitochondria function."

Journal • Preclinical • Genetic Disorders • Metabolic Disorders • Obesity • NAMPT

Comparative analysis of NAD+ boosters reveals the role of liver-nerve axis in metabolic health (EASL 2025) - "In a diet-induced mouse model of metabolic dysfunction-associated steatohepatitis (MASH), we compared the metabolic benefits of inhibiting PARP and SARM1 to the benchmark treatment of supplementing the NAD+ precursor nicotinamide riboside (NR). C57BL/6J mice were fed a western-style diet (WD) or chow at thermoneutrality (30°C) for 23 weeks with therapeutic treatment of NR (500 mg/kg/day), SARM1i (60 mg/kg/day), or olaparib (50 mg/kg/day) during the final 14 weeks... These findings suggest that increasing NAD+ levels through SARM1 inhibition alone can lead to comparable or greater metabolic benefits than NR, highlighting the importance of preserving nerve health for these effects. Furthermore, NR supplementation in vitro protects against nerve degeneration. Thus, preserving nerve health, including the function of the hepatic sympathetic nervous system, which is impaired in MASH, is central to the metabolic benefits of NAD+ elevation."

Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

NRVEERSAAM: NR vs. Vitamin E in Enhancing Fertility (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

New trial • Infertility • Sexual Disorders